Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $92.43

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $92.43.

RARE has been the topic of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Piper Sandler upped their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 22nd. Finally, TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RARE. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 294 shares during the period. Motley Fool Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 0.3% in the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock valued at $8,005,000 after purchasing an additional 360 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 493 shares during the period. Finally, KBC Group NV grew its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 506 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Up 2.7 %

RARE opened at $45.37 on Monday. The firm has a 50-day moving average price of $44.09 and a 200-day moving average price of $49.61. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -7.01 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. During the same quarter in the previous year, the firm posted ($2.23) EPS. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. On average, sell-side analysts expect that Ultragenyx Pharmaceutical will post -6.13 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.